Oncolys BioPharma Inc. (4588.T)
JPY 602.0
(-1.79%)
JPY 602.0
(-1.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 566.5 Million JPY | 15.21% |
| 2022 | 491.69 Million JPY | -29.55% |
| 2021 | 697.88 Million JPY | -12.0% |
| 2020 | 793.08 Million JPY | -14.35% |
| 2019 | 926 Million JPY | 75.06% |
| 2018 | 528.95 Million JPY | -11.0% |
| 2017 | 594.32 Million JPY | 13.65% |
| 2016 | 522.93 Million JPY | 3.66% |
| 2015 | 504.48 Million JPY | -20.84% |
| 2014 | 637.27 Million JPY | 5.69% |
| 2013 | 602.99 Million JPY | 83.9% |
| 2012 | 327.89 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 468.72 Million JPY | 18.49% |
| 2024 Q1 | 395.58 Million JPY | -30.17% |
| 2023 Q2 | 576.12 Million JPY | 29.42% |
| 2023 Q1 | 445.15 Million JPY | -9.46% |
| 2023 Q4 | 566.5 Million JPY | 24.74% |
| 2023 Q3 | 454.14 Million JPY | -21.17% |
| 2023 FY | 566.5 Million JPY | 15.21% |
| 2022 Q4 | 491.69 Million JPY | -49.96% |
| 2022 FY | 491.69 Million JPY | -29.55% |
| 2022 Q1 | 877.14 Million JPY | 25.69% |
| 2022 Q2 | 767.19 Million JPY | -12.53% |
| 2022 Q3 | 982.58 Million JPY | 28.08% |
| 2021 Q2 | 716.55 Million JPY | 3.2% |
| 2021 Q3 | 731.17 Million JPY | 2.04% |
| 2021 Q4 | 697.88 Million JPY | -4.55% |
| 2021 FY | 697.88 Million JPY | -12.0% |
| 2021 Q1 | 694.34 Million JPY | -12.45% |
| 2020 Q1 | 719.07 Million JPY | -22.35% |
| 2020 FY | 793.08 Million JPY | -14.35% |
| 2020 Q2 | 724.81 Million JPY | 0.8% |
| 2020 Q3 | 632.54 Million JPY | -12.73% |
| 2020 Q4 | 793.08 Million JPY | 25.38% |
| 2019 Q1 | 697.52 Million JPY | 31.87% |
| 2019 Q4 | 926 Million JPY | 43.36% |
| 2019 Q3 | 645.93 Million JPY | -7.44% |
| 2019 FY | 926 Million JPY | 75.06% |
| 2019 Q2 | 697.87 Million JPY | 0.05% |
| 2018 Q3 | 488.3 Million JPY | -5.78% |
| 2018 Q4 | 528.95 Million JPY | 8.32% |
| 2018 FY | 528.95 Million JPY | -11.0% |
| 2018 Q2 | 518.28 Million JPY | -6.11% |
| 2018 Q1 | 551.99 Million JPY | -7.12% |
| 2017 Q2 | 557.9 Million JPY | 20.79% |
| 2017 FY | 594.32 Million JPY | 13.65% |
| 2017 Q4 | 594.32 Million JPY | -2.62% |
| 2017 Q3 | 610.3 Million JPY | 9.39% |
| 2017 Q1 | 461.89 Million JPY | -11.67% |
| 2016 Q4 | 522.93 Million JPY | 7.9% |
| 2016 Q3 | 484.64 Million JPY | -6.31% |
| 2016 Q2 | 517.3 Million JPY | -12.12% |
| 2016 Q1 | 588.65 Million JPY | 16.68% |
| 2016 FY | 522.93 Million JPY | 3.66% |
| 2015 Q4 | 504.48 Million JPY | 2.28% |
| 2015 Q2 | 501.12 Million JPY | -5.9% |
| 2015 FY | 504.48 Million JPY | -20.84% |
| 2015 Q3 | 493.22 Million JPY | -1.58% |
| 2015 Q1 | 532.52 Million JPY | -16.44% |
| 2014 FY | 637.27 Million JPY | 5.69% |
| 2014 Q2 | 572.37 Million JPY | 9.15% |
| 2014 Q1 | 524.39 Million JPY | -13.03% |
| 2014 Q4 | 637.27 Million JPY | -0.32% |
| 2014 Q3 | 639.33 Million JPY | 11.7% |
| 2013 FY | 602.99 Million JPY | 83.9% |
| 2013 Q4 | 602.99 Million JPY | 0.0% |
| 2012 FY | 327.89 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 82.553% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -793.378% |
| GNI Group Ltd. | 26.34 Billion JPY | 97.849% |
| Linical Co., Ltd. | 10.3 Billion JPY | 94.503% |
| Trans Genic Inc. | 3.81 Billion JPY | 85.141% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 4.016% |
| Soiken Holdings Inc. | 697.02 Million JPY | 18.726% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 81.246% |
| AnGes, Inc. | 2.78 Billion JPY | 79.691% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -10.298% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.373% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -60.358% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 65.664% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -19.931% |
| CanBas Co., Ltd. | 91.98 Million JPY | -515.841% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 48.199% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 30.047% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 4.586% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 86.683% |
| PeptiDream Inc. | 29.11 Billion JPY | 98.054% |
| Ribomic Inc. | 155.8 Million JPY | -263.586% |
| SanBio Company Limited | 2.25 Billion JPY | 74.877% |
| Healios K.K. | 11.28 Billion JPY | 94.981% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -125.456% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -53.523% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -134.578% |
| StemRIM | 187 Million JPY | -202.941% |
| CellSource Co., Ltd. | 677.73 Million JPY | 16.413% |
| FunPep Company Limited | 189.32 Million JPY | -199.222% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 5.102% |
| Stella Pharma Corporation | 1.44 Billion JPY | 60.758% |
| TMS Co., Ltd. | 97.68 Million JPY | -479.902% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -519.166% |
| Cuorips Inc. | 200.96 Million JPY | -181.895% |
| K Pharma,Inc. | 209.13 Million JPY | -170.879% |
| Takara Bio Inc. | 11.42 Billion JPY | 95.039% |
| ReproCELL Incorporated | 741.03 Million JPY | 23.553% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 38.27% |
| StemCell Institute Inc. | 3.85 Billion JPY | 85.287% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 37.64% |
| CellSeed Inc. | 301.04 Million JPY | -88.177% |